Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 6, 2001, Pages 491-497

  Zhao, Liangli ^a   Kestell, Philip ^a   Philpott, Martin ^a   Ching, Lai Ming ^a   Zhuang, Li ^a   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bile; Colon 38; Glucuronide; Serotonin; TNF

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; CYPROHEPTADINE; GLUCURONIDE; NITRIC OXIDE; SEROTONIN; SEROTONIN ANTAGONIST; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON TUMOR; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG SENSITIVITY; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; CYPROHEPTADINE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; SEROTONIN ANTAGONISTS; TISSUE DISTRIBUTION; XANTHENES; XANTHONES;

EID: 0035001007     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000267     Document Type: Article

References (38)

1. 1. Baguley BC, Ching LM (1997) Immunomodulatory actions of xanthenone anticancer agents. Biodrugs 8: 119-127
2. 2. Baguley BC, Calveley SB, Crowe KK, Fray LM, O'Rourke SA, Smith GP (1989) Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on Colon 38 tumors in mice. Eur J Cancer Clin Oncol 25: 263-269
3. 3. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine - evidence for a vascular mechanism. Eur J Cancer 27: 482-487
4. 4. Baguley BC, Cole G, Thomsen LL, Zhuang L (1993) Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 33: 77-81
5. 5. Baguley BC, Zhuang L, Kestell P (1997) Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine -relation to vascular effects. Oncol Res 9: 55-60
6. 6. Baillie CT, Winslet MC, Bradley NJ (1995) Tumour vasculature - a potential therapeutic target. Br J Cancer 72: 257-267
7. 7. Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, Ching LM (1999) Thalidomide increases both intra-tumoral tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 80: 716-723
8. 8. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 25: 3666-3670
9. 9. Ching L-M, Xu Z-F, Gummer BH, Palmer BD, Joseph WR, Baguley BC (1995) Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 72: 339-343
10. 10. Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR (1994) Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys 29: 373-377
11. 11. Feng D, Nagy JA, Hipp J, Dvorak HF, Dvorak AM (1996) Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med 183: 1981-1986
12. 12. Fraser R, Day WA, Fernando NS (1986) Review: the liver sinusoidal cells their role in disorders of the liver, lipoprotein metabolism and atherogenesis. Pathology 18: 5-11
13. 13. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Kestell P (2000) Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Proc Am Soc Clin Oncol 19: 182a
14. 14. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching L-M (1999) Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 59: 633-638
15. 15. Kerr DJ, Kaye SB (1989) Flavone acetic acid - preclinical and clinical activity. Eur J Cancer Clin Oncol 25: 1271-1272
16. 16. Kestell P, Paxton JW, Rewcastle GW, Dunlop I, Baguley BC (1999) Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethyl-xanthenone-4-acetic acid in mouse, rat and rabbit. Cancer Chemother Pharmacol 43: 323-330
17. 17. Kestell P, Zhao L, Baguley BC, Palmer BD, Muller G, Paxton JW, Ching LM (2000) Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-actic acid (DMXAA) by thalidomide. Cancer Chemother Pharmacol 46: 135-141
18. 18. Kestell P, Zhao L, Ching L-M, Baguley BC, Zhou SF, Paxton J (2000) Effect of thalidomide (TH) and cyproheptadine (CPD) on the metabolism and excretion of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Proc Aust Soc Clin Exp Pharmacol Toxicol 7: 56
19. 19. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR (1998) Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78: 439-445
20. 20. Lautier D, Canitrot Y, Deeley RG, Cole SPC (1996) Multidrug resistance mediated by the multidrug resistance protein (mrp) gene. Biochem Pharmacol 52: 967-977
21. 21. Lienard D, Ewalenko P, Delmotte P, Renard JJ, Lejeune F (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52-60
22. 22. Mace KF, Hornung RL, Wiltrout RH, Young HA (1990) Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. Cancer Res 50: 1742-1747
23. 23. Manda T, Nishigaki F, Mori J, Shimomura K (1988) Important role of serotonin in the antitumor effects of tumor necrosis factor-alpha in mice. Cancer Res 48: 4250-4255
24. 24. Miners JO, Valente L, Lillywhite KJ, Mackenzie PI, Burchell B, Baguley BC, Kestell P (1997) Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res 57: 284-289
25. 25. Philpott M, Baguley BC, Ching L-M (1995) Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36: 143-148
26. 26. Ramu A, Ramu N (1992) Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol 30: 165-173
27. 27. Rewcastle GW, Kestell P, Baguley BC, Denny WA (1990) Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution. J Natl Cancer Inst 82: 528-529
28. 28. Rewcastle GW, Atwell GJ, Zhuang L, Baguley BC, Denny WA (1991) Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34: 217-222
29. 29. Rustin G, Galbraith S, Taylor N, Stratford M, Bradley C, Thompson P, Jameson M, Baguley B (1998) Impact on tumour perfusion measured by dynamic magnetic resonance imaging (MRI), in the phase 1 trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Proceedings of the Tenth NCI-EORTC Symposium on New Drugs 10: 126
30. 30. Smith GP, Calveley SB, Smith MJ, Baguley BC (1987) Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol 23: 1209-1212
31. 31. Starnes CO (1992) Coley's toxins in perspective. Nature 357: 11-12
32. 32. Thomsen LL, Ching LM, Zhuang L, Gavin JB, Baguley BC (1991) Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 51: 77-81
33. 33. Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N, Maeda M, Urushizaki I (1988) Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 48: 2179-2183
34. 34. Wilson WR, Baguley BC (2000) Combination of the antivascular agent DMXAA with radiation and chemotherapy. Int J Radiat Oncol Biol Phys 46: 706
35. 35. Wilson WR, Li AE, Cowan DSM, Siim BG (1998) Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Int J Rad Oncol Biol Phys 42: 905-908
36. 36. Wisse E, Braet F, Luo D, De Zanger R, Jans D, Crabbe E, Vermoesen A (1996) Structure and function of sinusoidal lining cells in the liver. Toxicol Pathol 24: 100-111
37. 37. Zwi LJ, Baguley BC, Gavin JB, Wilson WR (1989) Blood flow failure as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). J Natl Cancer Inst 81: 1005-1013
38. 38. Zwi LJ, Baguley BC, Gavin JB, Wilson WR (1994) Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 6: 79-85